Publication | Open Access

Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib

Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPathologyOncologyRadiation OncologyCancer ResearchHealth Sciences